Epi-R™ Technology Produces a Polyclonal TIL Product (LYL845) with a Greater Expansion Success Rate Across Hot & Cold Tumors, Improved Product Phenotype, & Maintenance of TCR Diversity.

Time: 2:15 pm
day: Day Two


  • Enrichment of CD8+ T-cells
  • Increased proportion of stem-like T-cells
  • Preservation of high clonal diversity
  • Higher proportion of stem-like CD8+ T cells and better expansion in products from samples with prior ICB